AdvaMed and other groups have released a public letter asking CMS to restore rapid coverage of FDA-approved "Breakthrough Devices." Similar coverage, called MCIT, was finalized by the first Trump admnistration but deleted by the Biden administration.
Find the information here:
- AdvaMed press release here.
- MedTechDive coverage here.
- Also, MedTechDive on the breadth of the BT program here.
- The actual PDF letter here.
- Also refers to a legislative approach, S 1717.
- The Senate bill could allow statutory changes not available to CMS alone.
